CLGN supply chain intelligence for CollPlant Biotechnologies Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CollPlant Biotechnologies Ltd. (CLGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| STEMCELL-TECHNOLOGIES | STEMCELL-TECHNOLOGIES | 92% | In December 2020, we entered into a product manufacturing and supply agreement with STEMCELL Technologies, or STEMCELL, a biotechnology company that develops and supplies specialized cell culture med… |
| DDD | 3D Systems Corporation | 72% | Reciprocal relationship from DDD graph: Reciprocal relationship from CLGN graph: development, both independently and with collaborators, of differentiated products in multiple industries with a short… |
| DDD | 3D Systems Corporation | 72% | development, both independently and with collaborators, of differentiated products in multiple industries with a short time to market. ● Utilize collaborative partners and distributors to develop and… |
| ENLV | Enlivex Ltd. | 72% | Reciprocal relationship from ENLV graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimat… |
| ESTA | Establishment Labs Holdings Inc. | 72% | Reciprocal relationship from ESTA graph: Reciprocal relationship from CLGN graph: an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galde… |
| ESTA | Establishment Labs Holdings Inc. | 72% | an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: nd optimization of growing techniques, and introduction of online controls. Our next-generation tobacco plants have be… |
| JNJ | Johnson & Johnson | 72% | nd optimization of growing techniques, and introduction of online controls. Our next-generation tobacco plants have been created through improved genetics and cross-breeding. In addition, increased g… |
| UTHR | United Therapeutics Corporation | 72% | Reciprocal relationship from UTHR graph: Reciprocal relationship from CLGN graph: elays in recruiting suitable patients to participate in our clinical trials; 14 Table of Contents ● imposition of a c… |
| UTHR | United Therapeutics Corporation | 72% | elays in recruiting suitable patients to participate in our clinical trials; 14 Table of Contents ● imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc. | 72% | Reciprocal relationship from ESTA graph: Reciprocal relationship from CLGN graph: an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galde… |
| ESTA | Establishment Labs Holdings Inc. | 72% | an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| IMCC | IM Cannabis Corp. | 72% | es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| IMCC | IM Cannabis Corp. | 72% | Reciprocal relationship from IMCC graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from IMCC graph: Reciprocal relationship from CLGN graph: es and marketing organization, for … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: nd optimization of growing techniques… |
| JNJ | Johnson & Johnson | 72% | nd optimization of growing techniques, and introduction of online controls. Our next-generation tobacco plants have been created through improved genetics and cross-breeding. In addition, increased g… |
| KLIC | Kulicke and Soffa Industries, Inc. | 72% | Reciprocal relationship from KLIC graph: Reciprocal relationship from CLGN graph: es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in … |
| KLIC | Kulicke and Soffa Industries, Inc. | 72% | es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| RGNT | Regentis Biomaterials Ltd. | 72% | Reciprocal relationship from RGNT graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from RGNT graph: Reciprocal relationship from CLGN graph: es and marketing organization, for … |
| RGNT | Regentis Biomaterials Ltd. | 72% | es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| UTHR | United Therapeutics Corporation | 72% | NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued) Revenues from licensing agreement On October 19, 2018, the Company signed a License, Development and Commercialization Agreement (the “License Agree… |
| UTHR | United Therapeutics Corporation | 72% | Reciprocal relationship from UTHR graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from UTHR graph: Reciprocal relationship from CLGN graph: NOTE 2—SIGNIFICANT ACCOUNTING POLIC… |
| ARTERIOCYTE-MEDICAL-SYSTEMS-INC | ARTERIOCYTE-MEDICAL-SYSTEMS-INC | 62% | an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| COLLPLANT-LTD | COLLPLANT-LTD | 62% | d revenues of approximately $2.4 million, mainly attributable to a development milestone achievement relating to the dermal filler product candidate, which triggered a $2 million payment from AbbVie … |
| GRAND-VIEW-RESEARCH-INC | GRAND-VIEW-RESEARCH-INC | 62% | ength due to alignment of the collagen fibers, and higher levels of transparency. In addition, rhCollagen can be used to produce high concentration solutions of collagen at lower viscosities at room … |
| MENTOR-WORLDWIDE-LLC | MENTOR-WORLDWIDE-LLC | 62% | an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| ZIMMER-BIOMET-HARVEST-TECHNOLOGIES-CORPORATION | ZIMMER-BIOMET-HARVEST-TECHNOLOGIES-CORPORATION | 62% | an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CLGN-DEBT | Debt stack $351,000 | 90% | Market cache reports total debt of $351,000. |
| CLGN-DEBT-8679 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| CLGN-DEBT-8678 | Warrants outstanding: 72000 | 90% | xbrl warrant detail from xbrl 2025-06-02. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CLGN-OWNER-PARALLEL-ADVISORS-LLC | Parallel Advisors, LLC | 90% | 13F overlay lists Parallel Advisors, LLC as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| AURA | Aura Biosciences, Inc. | 100.00 | 2 | |
| ESTA | Establishment Labs Holdings Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| CMND | Clearmind Medicine Inc. | 100.00 | 2 | |
| DDD | 3D Systems Corporation | 100.00 | 1 | ['supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ATON | AlphaTON Capital Corp | 100.00 | 2 |